Forever Health

Introduction

When Ozempic first reached pharmacies, most people saw it as a diabetes drug. Within a few years, it became synonymous with rapid weight loss, celebrity endorsements, and nationwide shortages. But in 2026, the conversation around GLP-1 receptor agonists — a class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — has shifted dramatically. These medications now stand at the center of one of medicine’s most exciting frontiers: not just as weight-loss tools, but as potential protectors of the heart, brain, and metabolic system.

A recent survey of clinical experts named GLP-1 medications the single most impactful health trend of 2026, with 52% of polled clinicians citing them as the area of highest ongoing research interest. New studies are emerging almost monthly, revealing therapeutic benefits that extend well beyond the bathroom scale — from reducing the risk of heart attacks to potentially slowing cognitive decline. Whether you’re considering these medications or simply curious about the science, here’s what the latest research and leading experts are saying about GLP-1 drugs and their expanding role in human health.

What the Experts Are Saying

Dr. Andrew Huberman and neuroscientist Dr. Zachary Knight — a professor of physiology at the University of California, San Francisco — have explored the neurological underpinnings of GLP-1 drugs extensively. According to Dr. Knight, semaglutide works by amplifying the body’s natural hunger-suppressing signal by up to 10,000-fold over baseline levels. “The hypothalamus plays a central role in how these drugs suppress hunger,” Knight has noted. “These are not simply gut drugs — they act directly in the brain.” This central mechanism explains the profound and sustained reduction in appetite that patients and clinical trials consistently report.

Longevity physician Dr. Peter Attia has been particularly focused on the cardiovascular data. Attia has repeatedly highlighted the landmark SELECT trial, which enrolled over 17,500 non-diabetic patients with overweight or obesity who had established cardiovascular disease. Participants taking semaglutide experienced a 20% relative reduction in major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — compared to placebo over an average follow-up of more than three years. “This was the first pharmacotherapy for overweight and obesity to reduce hard cardiovascular endpoints in a non-diabetic population,” Attia has observed. “That is a remarkable and clinically meaningful finding.”

Both Huberman and Attia also emphasize an important caveat: GLP-1 medications can cause significant lean mass loss alongside fat loss, making resistance training and adequate protein intake essential companions to any GLP-1 regimen.

The Science Behind It

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the intestines after eating. Under normal conditions, it signals the pancreas to secrete insulin, slows gastric emptying to increase satiety, and communicates with the hypothalamus to dial down appetite. GLP-1 receptor agonists mimic this hormone but with a far longer half-life — weekly injections maintain continuous receptor activation, producing a sustained suppression of hunger that the body’s brief, meal-triggered GLP-1 pulses cannot match.

Beyond the gut and brain, emerging research shows that GLP-1 receptors are also present in cardiovascular tissue, the liver, and potentially regions of the brain involved in reward and cognition. This distribution may explain the drug’s cardiovascular benefits, its apparent effect on reducing addictive cravings, and early evidence of neuroprotective properties. Tirzepatide adds a second mechanism by co-activating GIP (glucose-dependent insulinotropic polypeptide) receptors alongside GLP-1, producing even greater metabolic effects — including 15–25% total body weight loss in clinical trials, approaching outcomes once reserved for bariatric surgery.

A March 2026 study from the Cleveland Clinic also confirmed that discontinuing GLP-1 medications typically leads to significant weight regain, underscoring the chronic nature of obesity as a disease and the need for long-term treatment strategies.

Key Benefits

• Substantial, sustained weight loss: Semaglutide produces 10–16% total body weight reduction on average; tirzepatide achieves 15–25%, comparable to surgical interventions.
• Cardiovascular protection: The SELECT trial showed a 20% relative reduction in heart attacks, strokes, and cardiovascular death — even in non-diabetic patients with obesity.
• Improved insulin sensitivity and blood sugar control: GLP-1 drugs reduce HbA1c levels and improve metabolic markers in both diabetic and non-diabetic patients.
• Reduced addictive cravings: Patients frequently report decreased desire for alcohol, nicotine, and compulsive eating — consistent with GLP-1 receptor activity in brain reward circuits.
• Anti-inflammatory effects: Research suggests GLP-1 agonists reduce systemic inflammation, with potential benefits in metabolic-associated fatty liver disease (MAFLD) and inflammatory conditions.
• Emerging neuroprotective potential: Early clinical and preclinical data point to possible protective effects against cognitive decline, with GLP-1 agonists currently in trials for Alzheimer’s and Parkinson’s disease.

How to Get Started

GLP-1 receptor agonists are prescription medications, so the essential first step is a thorough consultation with a primary care physician, endocrinologist, or obesity medicine specialist. Bring a complete medical history, including any personal or family history of thyroid cancer, pancreatitis, or kidney disease. If prescribed, most patients begin at a low dose and titrate up gradually over several weeks to minimize gastrointestinal side effects.

Both Dr. Huberman and Dr. Attia strongly recommend pairing GLP-1 therapy with at least two to three resistance training sessions per week and a diet emphasizing adequate protein (0.7–1.0 grams per pound of target body weight daily). Tracking body composition — not just the number on the scale — helps ensure that the weight being lost is fat rather than muscle. Regular follow-up appointments every three months allow dose adjustments and monitoring of metabolic and body composition markers.

What to Watch Out For

GLP-1 medications carry an FDA boxed warning for potential risk of thyroid C-cell tumors and should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — particularly during dose escalation phases.

Lean mass loss is a serious and often underappreciated risk. Research cited by Dr. Attia indicates that a significant proportion of weight lost on GLP-1 medications comes from muscle and bone, not just fat — which can worsen long-term health trajectories if not proactively managed. Additionally, these medications appear to require indefinite use: data consistently show that most patients regain the majority of lost weight within one to two years of stopping. Cost and insurance coverage remain significant barriers, as monthly out-of-pocket costs can exceed $1,000 without coverage. Anyone with a history of pancreatitis, severe kidney disease, or diabetic retinopathy should consult their physician before starting therapy.

Watch the Full Expert Videos

For a deeper dive into the science and clinical nuances of GLP-1 medications, the following expert discussions are highly recommended:

Andrew Huberman & Dr. Zachary Knight (Huberman Lab): How Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? — The Science of Hunger & Medications to Combat Obesity

Dr. Peter Attia (The Drive / Early Medical): GLP-1 Agonists for Weight Loss — Efficacy, Benefits, Risks & Considerations

Expert Deep Dive: GLP-1 & Ozempic: Science and Practical Strategies You Need to Know